biostudies-literatureUnknown81(5)Chen HS<h4>Importance</h4>Dual antiplatelet therapy has been demonstrated to be superior to single antiplatelet in reducing recurrent stroke among patients with transient ischemic attack or minor stroke, but robust evidence for its effect in patients with mild to moderate ischemic stroke is lacking.<h4>Objective</h4>To evaluate whether dual antiplatelet therapy is superior to single antiplatelet among patients with mild to moderate ischemic stroke.<h4>Design, setting, and participants</h4>This was a multicenter, open-label, blinded end point, randomized clinical trial conducted at 66 hospitals in China from December 20, 2016, through August 9, 2022. The date of final follow-up was October 30, 2022. The analysis was reported on March 12, 2023. Of 3065 patients with ischemic stroke, 3000 patients wJAMA neurology450-460https://www.ebi.ac.uk/biostudies/studies/S-EPMC10928538biostudies-literatureClopidogrel Plus Aspirin vs Aspirin Alone in Patients With Acute Mild to Moderate Stroke: The ATAMIS Randomized Clinical Trial.PMC10928538Liu HMWang WZATAMIS investigatorsQiu XFChen HSLiang YChen HRQiu XRDu YDuan YJWang HWang XHHai YJu XHZhang PWang NSong YLZhang LYLiu YJMeng ZMZhang YTLin YZHuang SMZhang QHLi HLi JChen SYWang LQWang DLWei YFXu ZXZhang HLGong XHXu JSheng BYLi DQHe ZLWang DYLiu CYLu JTao DBGuo YQJiang CHWang ZBLi RHZhu XCZhao YZhang SYShen LYZhao LHNguyen TNXue WSXiao HBHong MSong CGBai FSZhang JTLi JYMa YTZhang WYuan ZMMeng CHan BPan PKCui YSong XHJiang LYZhao CGHan JZou RLHe XMfalseClopidogrel Plus Aspirin vs Aspirin Alone in Patients With Acute Mild to Moderate Stroke: The ATAMIS Randomized Clinical Trial.<h4>Importance</h4>Dual antiplatelet therapy has been demonstrated to be superior to single antiplatelet in reducing recurrent stroke among patients with transient ischemic attack or minor stroke, but robust evidence for its effect in patients with mild to moderate ischemic stroke is lacking.<h4>Objective</h4>To evaluate whether dual antiplatelet therapy is superior to single antiplatelet among patients with mild to moderate ischemic stroke.<h4>Design, setting, and participants</h4>This was a multicenter, open-label, blinded end point, randomized clinical trial conducted at 66 hospitals in China from December 20, 2016, through August 9, 2022. The date of final follow-up was October 30, 2022. The analysis was reported on March 12, 2023. Of 3065 patients with ischemic stroke, 3000 patients w2024-01-01T00:00:00Z2024 May2026-06-01T20:13:04.226Z2025-04-06T08:32:27.203ZS-EPMC109285383846627410.1001/jamaneurol.2024.0146